ArticleScientific reports2025
Associations of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with all-cause and cardiovascular mortality among general population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is a novel lipid indicator for predicting mortality across populations, but its link to mortality in the general population is underestimated. A total of 17,334 participants from the US National Health and Nutrition Examination Survey (2005-2018) were analyzed. Weighted Cox proportional hazards models were employed to investigate the association between NHHR and all-cause and cardiovascular (CVD) mortality. We employed restricted cubic splines (RCS) to assess potential nonlinear relationships. Over a median follow-up of 88 months, we documented 1878 deaths. According to the RCS analysis, NHHR exhibited an L-shaped association with all-cause and CVD mortality. Inflection points were identified at NHHR = 2.30 for all-cause mortality and NHHR = 2.64 for CVD mortality. Below these thresholds, each unit increase in NHHR was associated with a 39% reduction in all-cause mortality (HR: 0.61, 95% CI 0.50-0.75) and a 34% reduction in CVD mortality (HR: 0.66, 95% CI 0.50-0.88). Above these thresholds, no significant associations were observed. Subgroup analyses revealed stronger inverse associations in adults aged ≥ 60 years (P for interaction < 0.0001) and those with underweight or overweight statuses (P = 0.0032). Our findings highlight an L-shaped association between NHHR and both all-cause and cardiovascular disease (CVD) mortality. NHHR demonstrates potential as a novel biomarker for personalized mortality risk stratification, particularly in high-risk subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.